(4R)-3-[(2S,3S)-3-[[(2S)-2-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethylbutanoyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-(cyclopropylmethyl)-5,5-dimethyl-1,3-thiazolidine-4-carboxamide | 1061337-11-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (4R)-3-[(2S,3S)-3-[[(2S)-2-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethylbutanoyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-(cyclopropylmethyl)-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
• CAS: 1061337-11-8
• 化学式: C₃₄H₄₇N₅O₅S
• 分子量: 637.844
• InChiKey: OIEMGASMKFTAFB-APNLASKRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  45
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  179
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  异戊酸 、 (4R)-3-[(2S,3S)-3-[[(2S)-2-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethylbutanoyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-(cyclopropylmethyl)-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 以17%的产率得到(4R)-N-(cyclopropylmethyl)-3-[(2S,3S)-3-[[(2S)-3,3-dimethyl-2-[[(2S)-2-(3-methylbutanoylamino)-2-phenylacetyl]amino]butanoyl]amino]-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
  参考文献：
  名称：

  Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme

  摘要：

  Adult T-cell leukemia and tropical spastic paraparesis/ HTLV-I-associated myelopathy are only some of the more common end results of an infection with a human T-cell leukemia virus type 1 (HTLV-I). Expanding from our previous reports, we synthesized all different permutations of tetrapeptidic HTLV-I protease inhibitors using at least eight P3-cap and five P(1)'-cap moieties. The inhibitors exhibited over 97% inhibition against HIV-1 protease and a wide range of inhibitory activity against HTLV-I protease. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.05.052
• 作为产物：
  描述：

  在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 (4R)-3-[(2S,3S)-3-[[(2S)-2-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethylbutanoyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-(cyclopropylmethyl)-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
  参考文献：
  名称：

  Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme

  摘要：

  Adult T-cell leukemia and tropical spastic paraparesis/ HTLV-I-associated myelopathy are only some of the more common end results of an infection with a human T-cell leukemia virus type 1 (HTLV-I). Expanding from our previous reports, we synthesized all different permutations of tetrapeptidic HTLV-I protease inhibitors using at least eight P3-cap and five P(1)'-cap moieties. The inhibitors exhibited over 97% inhibition against HIV-1 protease and a wide range of inhibitory activity against HTLV-I protease. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.05.052

文献信息

• Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors
  作者：Jeffrey-Tri Nguyen、Meihui Zhang、Henri-Obadja Kumada、Ayako Itami、Keiji Nishiyama、Tooru Kimura、Maosheng Cheng、Yoshio Hayashi、Yoshiaki Kiso

  DOI：10.1016/j.bmcl.2007.10.066

  日期：2008.1

  The culprit behind adult T-cell leukemia, myelopathy/tropical paraparesis, and a plethora of inflammatory diseases is the human T-cell leukemia virus type 1 (HTLV-1). We recently unveiled a potent hexapeptidic HTLV-1 protease inhibitor, KNI-10166, composed mostly of natural amino acid residues. Herein, we report the derivation of potent tetrapeptidic inhibitor KNI-10516, possessing only non-natural amino acid residues. (C) 2007 Elsevier Ltd. All rights reserved.
• Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme
  作者：Meihui Zhang、Jeffrey-Tri Nguyen、Henri-Obadja Kumada、Tooru Kimura、Maosheng Cheng、Yoshio Hayashi、Yoshiaki Kiso

  DOI：10.1016/j.bmc.2008.05.052

  日期：2008.7

  Adult T-cell leukemia and tropical spastic paraparesis/ HTLV-I-associated myelopathy are only some of the more common end results of an infection with a human T-cell leukemia virus type 1 (HTLV-I). Expanding from our previous reports, we synthesized all different permutations of tetrapeptidic HTLV-I protease inhibitors using at least eight P3-cap and five P(1)'-cap moieties. The inhibitors exhibited over 97% inhibition against HIV-1 protease and a wide range of inhibitory activity against HTLV-I protease. (c) 2008 Elsevier Ltd. All rights reserved.